Find a Member

Search by Name
Search by Keyword
Search by Program
Search by Theme
View Investigators by Last Name
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z


Jonathan Alder
Program(s): Genome Stability
Nduka Amankulor
Program(s): Cancer Biology
Research Interests and Keywords:
  • Microenvironment and immune escape in glioblastoma
  • oligodendroglioma
  • brain and spine metastases
Leonard Appleman, MD, PhD
Program(s): Cancer Therapeutics
UPMC Cancer Pavilion
5230 Center Ave., Suite 567
Pittsburgh PA
Phone: 412-648-6507
Research Interests and Keywords:
  • Kidney cancer and other genitourinary malignancies
  • experimental cancer therapeutics
Maninjay Atianand
Program(s): Cancer Immunology and Immunotherapy
Daniel Altschuler
Program(s): Cancer Therapeutics
Biomedical Science Tower, E-1348
200 Lothrop Street
Pittsburgh PA
Phone: 412-648-9751
Carolyn Anderson, PhD
Program(s): Cancer Immunology and Immunotherapy
100 Technology Drive
Bridgeside Point Suite 452
Pittsburgh PA
Research Interests and Keywords:
  • Radiopharmaceuticals
  • metal radionuclides
  • diagnostic imaging
  • cancer imaging
  • radiotherapy
  • molecular imaging
  • positron emission tomography (PET)
  • cancer metastasis
The major focus of the Anderson Lab is the development, evaluation and application of radiopharmaceuticals containing metal radionuclides for diagnostic imaging and radiotherapy. We are particularly interested in 64Cu (T1/2 = 12.7 hours), in large part because it emits beta+ particles for positron emission tomography (PET) imaging and beta- particles for targeted radiotherapy. We are also investigating 68Ga (T1/2 = 68 min) as a generator-produced positron-emitting radionuclide. The agents we are studying are 64Cu- and 68Ga-labeled chelator-peptide and monoclonal antibody conjugates for imaging and/or therapy of various types of cancer. One area of investigation in our laboratory is the development of radiolabeled alpha vs. beta 3 integrin ligands as PET agents for imaging bone metastasis. We have developed one agent, 64Cu-CB-TE2A-c(RGDyK), that specifically binds to alpha vs. beta 3 integrin in osteoclasts, which are bone resorbing cells that are present in high concentration in osteolytic bone lesions. This agent may be able to earlier detect painful, debilitating bone lesions associated with breast cancer, and multiple myeloma, as well as be used to determine early response to treatment of bone lesions associated with these diseases. Another area of focus for our lab is investigating imaging agents that target cell types, other than tumor cells, involved in cancer metastasis. For example, we are targeting integrin alpha 4 beta 1 as a marker of bone marrow derived cells that home to sites of metastasis prior to tumor cells as part of the pre-metastatic niche. We are also investigating immune cell types, such as macrophages, neutrophils and T-cells and their role in cancer and other diseases.
Karen Arndt, PhD
Program(s): Genome Stability
A316 Langley Hall
4249 Fifth Ave
Pittsburgh PA
Phone: 412-624-6963
Research Interests and Keywords:
  • Gene expression
  • cellular transcription
  • mRNA synthesis
  • RNA polymerase II
  • chromatin
A critical question to ask, particularly in this genomic era, is how organisms interpret the vast amounts of information encoded in their genomes. The Arndt lab studies the first step in gene expression, the synthesis of mRNA by RNA polymerase II, with a focus on the mechanisms that regulate transcription in the chromatin environment of a eukaryotic cell. The fundamental importance of understanding transcriptional regulation is evident from the large number of human developmental defects and diseases, including cancer and AIDS, that arise when cellular transcription factors are altered by mutation or commandeered by viral proteins.